Share on Facebook Share on Twitter

Thread Rating:
  • 0 Vote(s) - 0 Average
  • 1
  • 2
  • 3
  • 4
  • 5
May 2022 study re antibodies after 2 or 3 Pfizer doses
Currently it seems the research reports getting into the news are scattered, and are getting interpreted according to the perspectives of the news organizations.

For instance, this research letter dated 13 May 2022
Neutralizing Antibodies Against the SARS-CoV-2 Omicron Variant (BA.1) 1 to 18 Weeks After the Second and Third Doses of the BNT162b2 mRNA Vaccine

Their main claim is "Our study found a rapid decline in Omicron-specific serum neutralizing antibody titers only a few weeks after the second and third doses of BNT162b2."  It appears that this was opportunistic and done without the knowledge of the subjects. "This study constitutes national infectious disease surveillance performed on excess biological material".  Accordingly, it was a small study (some results are based on less than 10 measurements (some with 3 or 4 at one end point) so outliers impact the results).

Some inconsistencies bug me about this study.  Sometimes the "50% Serum neutralization titer" values are presented as logarithms and sometimes as linear.  Sometimes their results are about the titer value (and they present results as multiplicative levels of the geometric mean titer), and sometimes their results are percentages about the ability to measure the titer value (minimum of 10).

I was put off by the use of the terms "rapid" and "only" in their main claim.  It presumes a particular rate which I don't see specified.

I would say that whatever this study found might be suggestive of something to measure, not a valid measurement itself.
I agree with your conclusion that the news reports are scattered.   I"ll go further and state that the scattered reports are really confusion people on if they should get a booster or not.   I do hope for someone simpler info after July when supposedly Pfizer and MOderna will finalize an updated "recipe"

Forum Jump:

Users browsing this thread: